Skip to main content

Immunotherapeutic Strategies For The Treatment Of Glioma

In Order to Read Online or Download Immunotherapeutic Strategies For The Treatment Of Glioma Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Immunotherapeutic Strategies for the Treatment of Glioma

Immunotherapeutic Strategies for the Treatment of Glioma Book
Author : Christopher Jackson,Michael Lim
Publisher : Academic Press
Release : 2021-09-10
ISBN : 0128197560
Language : En, Es, Fr & De

GET BOOK

Book Description :

Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward. The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics. This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma. Summarizes the work in immunotherapy for glioma to-date, including the available evidence from preclinical studies and clinical trials Reviews the challenges and successes of the most promising strategies for brain tumor immunotherapy Provides a foundation for considering novel and combination therapies moving forward

Brain Tumor Immunotherapy

Brain Tumor Immunotherapy Book
Author : Linda M. Liau,Donald P. Becker,Timothy F. Cloughesy,Darell D. Bigner
Publisher : Springer Science & Business Media
Release : 2000-11-10
ISBN : 1592590357
Language : En, Es, Fr & De

GET BOOK

Book Description :

An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.

Glioblastoma

Glioblastoma  Book
Author : Swapan K. Ray
Publisher : Springer Science & Business Media
Release : 2009-10-31
ISBN : 1441904107
Language : En, Es, Fr & De

GET BOOK

Book Description :

Glioblastoma is the most malignant brain tumor that still remains incurable. It is such a deadly disease that patients do not survive more than a few months after diagnosis. Our understanding of the histopathology and molecular mechanisms of formation of glioblastoma is rapidly advancing so as to provide us clues for devising rational therapeutic strategies for treatment of this malignancy. It is important that we continue to improve our knowledge about the pathogenesis of this devastating disease and explore new areas to find successful therapeutic strategies. Various approaches such as sophisticated imaging techniques, improved surgical procedures, ground-breaking strategies for radiotherapy, chemotherapy, immunotherapy, chemoimmunotherapy, and photodynamic therapy are being used for eradicating glioblastoma. Hopefully, this book will be an important source of information on glioblastoma and therefore be highly useful to the students, postdoctoral fellows, principal investigators, and clinicians involved in this field.

Intracranial Gliomas Part III Innovative Treatment Modalities

Intracranial Gliomas Part III   Innovative Treatment Modalities Book
Author : M.F. Chernov,Y. Muragaki,S. Kesari,I.E. McCutcheon
Publisher : Karger Medical and Scientific Publishers
Release : 2018-07-10
ISBN : 3318060631
Language : En, Es, Fr & De

GET BOOK

Book Description :

At present most intracranial gliomas are considered incurable with current treatment strategies, and the search for new modalities that may effectively control tumor growth continues. The chapters in this volume describe basic principles and therapeutic possibilities of several innovative techniques, including photodynamic therapy, laser-induced interstitial thermotherapy, stereotactic cryodestruction, high-intensity focused ultrasound ablation, boron neutron capture therapy, proton and carbon ion irradiation, targeted therapy, immunotherapy, gene therapy, local chemotherapy, and alternating electric fields therapy. Potential applications of extracellular vesicles and nanotechnology for management of gliomas are highlighted as well. Many of these methods have already demonstrated antitumor efficacy in clinical testing, whereas others are still under development. The materials presented in this book are mainly directed at clinicians treating patients with brain tumors, as well as clinical and basic researchers working in the field of neuro-oncology.

Enhancing Immunity to Glioma Modulating the Adaptive Immune Response in the Tumor Microenvironment

Enhancing Immunity to Glioma  Modulating the Adaptive Immune Response in the Tumor Microenvironment Book
Author : Joseph Paul Antonios
Publisher : Unknown
Release : 2016
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Glioblastoma (GBM) is the most common and lethal of all adult primary malignant brain tumors. For patients diagnosed with GBM, the median survival is 11-14 months despite advances in surgical resection techniques, chemotherapies, and radiation therapy (1). Alternate therapeutic strategies are being actively pursued to target GBM, with various immunotherapeutic modalities designed to generate an anti-GBM immune response showing considerable promise in preclinical models and clinical trials. To more effectively target GBM with these treatments, there has been an increasing appreciation of the numerous mechanisms involved in generating and maintaining the highly immunosuppressive tumor microenvironment in recent years. These studies have described a variety of microenvironmental and systemic factors that promote glioma cell evasion from the immune system. In light of these, it has become apparent that these factors must be understood and explicitly targeted to mount a successful immune response against GBM. This thesis describes the utilization of two different immunotherapeutic strategies to target GBM. The first strategy created a novel GBM target by inducing NY-ESO-1 antigen expression with the demethylating agent, decitabine, and targeting that antigen with engineered T cells. Specifically, we utilized human GBM cell cultures to induce expression of the antigen. We evaluated NY-ESO-1 TCR-transduced T cell-mediated GBM tumor cytolysis in a series of in vitro cytotoxicity assays. Following this, we examined the application of this therapy using an intracranially-implanted xenograft model. Our studies demonstrated that decitabine could effectively upregulate NY-ESO-1 both in vivo and in vitro. Engineered T cells were able to induce tumor cytolysis in vitro and were able to traffic to and target tumor in vivo. Tumor-bearing mice receiving adoptive transfer of these engineered T cells demonstrated significantly increased survival over mice that received non-transduced T cells. By inducing expression of a novel target on GBM, we were able to generate a highly specific, anti-GBM immune response. This strategy represented a clinically translatable therapeutic technique for treating patients with GBM. The second strategy focused on using existing GBM targets to generate an endogenous immune response in a syngeneic, immune competent mouse model. Briefly, we administered an autologous tumor lysate-pulsed dendritic cell (DC) vaccine to produce a glioma-specific immune response. In our studies, the vaccination appeared to be capable of inducing T cell infiltration into tumors; however, in large, established tumors, this infiltrating response was not sufficient to increase mouse survival and provide significant therapeutic benefit. We described the role of the negative costimulatory pathway, programmed death-1/ligand-1 (PD-1/PD-L1) in mitigating T cell activation and memory in a series of in vitro and in vivo studies. We noted that PD-1 blockade with PD-1 mAb was not sufficient to produce a T cell infiltrate. However, when administered with DC vaccination, PD-1 blockade activated the vaccine-generated T cell response in the tumor microenvironment. We found that T cells with PD-1 mAb were able to mediate significant tumor cytolysis when compared to T cells without PD-1 blockade in vitro. The adjuvant administration of PD-1 mAb with the DC vaccine resulted in significant survival benefit over DC vaccine alone in mice bearing large, established gliomas. Additionally, this dual treatment resulted in the increased expression of integrin homing and immunologic memory markers on T cells infiltrating tumor. These findings were corroborated in samples from patient GBM, with PD-1 blockade enhancing the T cell-mediated GBM cytolysis. Concerning this strategy, then, these findings provided us with a means to both generate and enhance a tumor-specific response. While this second strategy proved effective, the mechanism underlying this PD-1/PD-L1-mediated suppression was not fully understood. As such, we proceeded to identify a PD-L1-expressing tumor infiltrating myeloid (TIM) cell population that appeared to dominantly regulate the PD-1/PD-L1 signaling mechanism. Importantly, we determined the role that these cells play in inhibiting the immune response using a series of in vitro and in vivo studies utilizing TIM depletion and PD-1 mAb treatment strategies. We found that depletion of TIMs in both human GBM cultures and murine glioma abolished PD-1/PD-L1-mediated inhibition of T cell activation. Targeting TIMs with colony stimulating factor-1 receptor inhibitor (CSF-1Ri) reduced the TIM population significantly and altered the remaining TIMs such that they demonstrated increased expression of chemotactic factors. While treatment with CSF-1Ri in conjunction with DC vaccine did not alter PD-L1 expression on remaining TIMs, we did note that there was increased TIL infiltration with this dual treatment significantly over DC vaccine alone. These findings suggested that TIMs exert inhibitory effects in the tumor microenvironment in a manner not restricted only to the PD-1/PD-L1 signaling mechanism. We found that the combined treatment of CSF-1Ri and PD-1 mAb with DC vaccination both increased TIL infiltration and activation in the tumor microenvironment. These findings were therapeutically relevant, with tumor-bearing mice receiving all three treatments showing a significant increase in survival over mice receiving each treatment alone. The studies outlined herein elucidated the role that TIMs play in dominantly mediating the PD-1/PD-L1 signaling mechanism to restrict TIL activation, as well as the ability to manipulate this population pharmacologically with clinically accessible agents. In conclusion, this thesis demonstrates two distinct strategies to generate and enhance an immune response against GBM. In our first strategy, we utilized the adoptive transfer of engineered T cells to selectively target an antigen whose expression we artificially induced in GBM. This technique was largely effective. However, we were interested in directly targeting antigens already expressed by GBM. To that end, we described the utility of DC vaccination in generating an immune response. Further, we delineated the inhibitory mechanisms employed by TIMs in the tumor microenvironment and developed a therapeutic adjuvant to administer with DC vaccination. We confirmed the efficacy of these treatments in a series of in vitro and in vivo animal studies, and we recapitulated these findings in our novel, ex vivo human GBM studies. Together, the studies presented in this thesis represent an innovative approach to understanding and immunotherapeutically targeting the GBM microenvironment.

Modern Management of High Grade Glioma Part II An Issue of Neurosurgery Clinics E Book

Modern Management of High Grade Glioma  Part II  An Issue of Neurosurgery Clinics   E Book Book
Author : Isaac Yang,Seunggu J. Han
Publisher : Elsevier Health Sciences
Release : 2012-07-15
ISBN : 1455747688
Language : En, Es, Fr & De

GET BOOK

Book Description :

Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts on management of high grade glioma. Some of the articles in this issue include: Use of language mapping to aid resection of eloquent gliomas; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Nanotechnology potential applications for GBM therapy; High Grade Gliomas in children; Modern Advances in Brain Tumor Treatments; Molecular pathways of Avastin interactions for the treatment of glioblastoma; and Quality of Life and Outcomes in Glioblastoma management.

Frontiers in Clinical Drug Research Anti Cancer Agents Volume 7

Frontiers in Clinical Drug Research   Anti Cancer Agents  Volume 7 Book
Author : Atta-ur-Rahman
Publisher : Bentham Science Publishers
Release : 2021-07-07
ISBN : 1681087766
Language : En, Es, Fr & De

GET BOOK

Book Description :

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The seventh volume of the book features reviews on these topics: · Essential oils and monoterpenes as potential anti-cancer agents · Drug delivery systems and emerging immunotherapeutic strategies for the treatment of glioblastoma · CTDNA in solid tumors · Cholesterol treatments (including Pitavastatin) and their potential in cancer treatment

Glioma

Glioma Book
Author : ryuya yamanaka
Publisher : Springer Science & Business Media
Release : 2012-05-27
ISBN : 1461431468
Language : En, Es, Fr & De

GET BOOK

Book Description :

Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.

Cancer Immunotherapy Mechanisms of Cancer Immunity Engineering Immune Based Therapies and Developing Clinical Trials

Cancer Immunotherapy  Mechanisms of Cancer Immunity  Engineering Immune  Based Therapies and Developing Clinical Trials Book
Author : Jianxun Song
Publisher : Bentham Science Publishers
Release : 2015-04-16
ISBN : 1681080486
Language : En, Es, Fr & De

GET BOOK

Book Description :

Clinicians, patients and scientists, alike, have been battling cancer for over several decades; however, patient outcomes have not significantly improved over the years with conventional therapies. In recent years, this has caused researchers to look for a change in the status quo, and, the awareness of the human immune system, which has an intrinsic mechanism to control microbial pathogens and dysfunctional self-tissues, has triggered scientists to look for new modes of cancer therapy. Cancer Immunotherapy has become a major research field as a result of these efforts, gaining some recognition for notable breakthroughs in cancer patient prognosis. Frontiers in Cancer Immunology collectively presents the methods which have been studied and used in cancer immunotherapy based on the different components of human immune system. The series will give clinicians and immunologists a roadmap of current trends in all branches of cancer immunology. This volume lists the major immune system components (such as T cells and NK cells and associated antigens/antibodies) which have been demonstrated to limit the growth of or kill tumor cells. Relevant applications in cancer therapy are also included in addition to a general introduction to engineered as well as targeted cancer immunotherapies (cancer vaccines).

Immunotherapy An Issue of Neurosurgery Clinics E Book

Immunotherapy  An Issue of Neurosurgery Clinics   E Book Book
Author : Isaac Yang,Michael J Lim
Publisher : Elsevier Health Sciences
Release : 2010-01-05
ISBN : 1455700452
Language : En, Es, Fr & De

GET BOOK

Book Description :

For this issue, Dr. Michael Lim of Johns Hopkins and Dr. Isaac Yang of UCSF team up to deliver a packed issue on the latest developments in Immunotherapy. The issue covers hot topics such as immunostimulants, Passive Antibody Mediated Immunotherapy, Clinical Applications of A Peptide Based Vaccine, Challenges for Clinical Design of Immunotherapy Trials, The EGFRv3 Peptide Vaccine, Stem Cell Therapy and Dendritic Cell Vaccines, Dendritic Glioma Fusion Vaccine, Adoptive Cellular Immunotherapy, Virus Mediated Immunotherapy, and so much more.

IDO1 Inhibitors in Combination with Immunotherapy for the Treatment of Glioblastoma

IDO1 Inhibitors in Combination with Immunotherapy for the Treatment of Glioblastoma Book
Author : Matthew William Phillip De Leeuw
Publisher : Unknown
Release : 2016
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

The immune system in patients with cancer is often markedly impaired, with tumours utilising a variety of methods to subvert anti-tumour immune responses. One mechanism whereby tumours can induce immune suppression involves increased expression of the enzyme indoleamine 2, 3-dioxygenase 1 (IDO1). This enzyme catalyses the degradation of the essential amino acid tryptophan along the kynurenine pathway. IDO1 is expressed in a broad range of cancers and is correlated with increased immune suppression and poor patient survival. IDO1 inhibitors would therefore be expected to be beneficial for restoring antitumour immunity in cancer patients. High throughput screening of compound libraries has led to the discovery of a novel chemical class of IDO1 inhibitors, from which SN35837 has been selected for development into a potential anti-cancer agent. Preliminary studies of SN35837 in a preclinical model of glioma have yielded encouraging results. Kynurenine:tryptophan (K:T) ratios are commonly used as an indicator of IDO1 activity, and a sensitive HPLC assay detecting both tryptophan and kynurenine concentrations in biological samples was established to measure K:T ratios in tissues collected from tumour bearing mice. Daily administration of SN35837 was shown to suppress K:T ratios in both tumour and plasma of tumour bearing mice, reflecting the ability of SN35837 to inhibit IDO1 activity. The level of K:T ratio suppression was dose dependent and lasted between 2 to 6 hours after treatment, depending on the dose. Preclinical studies have recently shown that combinatorial targeting of immunosuppression is a strategy that has high potential value for the treatment of cancer, including malignant glioma. With SN35837 identified as a potent inhibitor of IDO1, experiments were conducted to obtain proof-of-principle that combining IDO1 inhibition with other immunotherapeutic approaches could lead to improvements over monotherapy. To this end, SN35837 was tested in combination with PD-1 immune checkpoint blockade resulting in improved survival of tumour bearing mice. Combination of SN35837 with a whole cell glioma vaccine, however, did not provide improvements over control. The work in this thesis highlights the in vivo efficacy of SN35837 as an inhibitor of IDO1 and point to its combination with immune checkpoint blockade as a potential treatment for cancer.

Principles of Molecular Neurosurgery

Principles of Molecular Neurosurgery Book
Author : Andrew Freese
Publisher : Karger Medical and Scientific Publishers
Release : 2005-01-01
ISBN : 3805577842
Language : En, Es, Fr & De

GET BOOK

Book Description :

The future of neurosurgery will be characterized by less invasive, molecular technologies that promise to revolutionize the field of neurosurgery and impact the treatment of additional neurological disorders, including neurometabolic diseases, stroke, dementias, affective and psychiatric diseases, movement disorders, epilepsy, and others. This book encompasses developing an understanding of the principles underlying the advent of novel molecular approaches to neurological and neurosurgical diseases. It Identifies key principles that will allow dramatic improvement in the treatment and outcomes of patients suffering from a varity of disorders affecting the central nervous system and spinal axis. This volume gives neurosurgeons an excellent understanding of the development of novel molecular and cellular technologies that will markedly change the way neurosurgery is practiced in the near future. It is also of special interest to neurologists, psychiatrists, physiatrists, spinal orthopaedic surgeons, neurobiologists and gene therapy research scientists.

Oligodendroglioma

Oligodendroglioma Book
Author : Nina A. Paleologos,Herbert B. Newton
Publisher : Academic Press
Release : 2019-06-18
ISBN : 0128131594
Language : En, Es, Fr & De

GET BOOK

Book Description :

Oligodendroglioma: Clinical Presentation, Pathology, Molecular Biology, Imaging, and Treatment features the latest "cutting-edge" molecular biology, molecular therapeutics, imaging, immunotherapy, and research methods on the topic of oligodendrogliomas. The most detailed and comprehensive resource on the subject, it provides up-to-date information on clinical presentation, pathology, molecular biology, and treatment methods, including immunotherapy. This book is a critical for students, physicians and researchers in the fields of neuroscience, neuro-oncology, neurosurgery, radiation oncology, medical oncology, and others working in research or with patients. Provides the most up-to-date information regarding the clinical presentation, pathology, molecular biology, and methods for the treatment of oligodendroglioma brain tumors, including surgical therapy, radiotherapy, molecular therapeutics, chemotherapy, and immunotherapy Broadly appeals to anyone interested in the field of neuro-oncology and the treatment of patients with oligodendrogliomas Useful to clinicians interested in a thorough overview of the basic science and treatment of oligodendrogliomas Includes a section on immunotherapy, with updates on the use of vaccines and immune-based treatment approaches applied to oligodendrogliomas

Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor

Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor Book
Author : Terry Lichtor
Publisher : BoD – Books on Demand
Release : 2015-03-25
ISBN : 953512031X
Language : En, Es, Fr & De

GET BOOK

Book Description :

A dramatic increase in knowledge regarding the molecular biology of brain tumors has been established over the past few years. In particular, recent new avenues regarding the role of microRNAs along with further understanding of the importance of angiogenesis, immunotherapy and explanations for the resistance of the tumors to radiation therapy have been developed. A discussion of certain surgical management issues including improvements in imaging along with issues concerning tumor induced epilepsy is included. It is hopeful that this new information will lead to efficacious treatment strategies for these tumors which remain a challenge. In this book, a review of the latest information on these topics along with a variety of new therapeutic treatment strategies with an emphasis on molecular targeted therapies is provided.

Malignant Gliomas RMR V3 I2

Malignant Gliomas  RMR V3 I2 Book
Author : Anonim
Publisher : Demos Medical Publishing
Release : 2012-10-09
ISBN : 1617051489
Language : En, Es, Fr & De

GET BOOK

Book Description :

Radiation Medicine Rounds is a trinary, hard cover periodical designed to provide an up-to-date review of a dedicated radiation medicine topic of interest to clinicians and scientists who are involved in the care of patients receiving radiotherapy. It is intended to serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinicians, medical physicists, cancer biologists, radiobiologists, and interdisciplinary colleagues throughout the oncology spectrum. This issue of Radiation Medicine Rounds discusses the more salient topics surrounding the role of radiation therapy for malignant gliomas. The specialty of radiation therapy has increased in complexity over the years, yet as technology improves, the goal of improving outcomes while decreasing toxicity remains critical. Malignant gliomas remain among the most devastating of all malignancies, yet as conventional treatments (surgery, radiation, and chemotherapy) have become optimized overall survival has improved. The underlying molecular and genetic mechanisms of these tumors are becoming better understood, with one of the most important realizations being that histopathologically identical malignant gliomas often demonstrate very distinct clinical behaviors. Malignant Gliomas provides the practitioner with a current overview of best practices, recent research, and future directions in the management of this complex and challenging cancer.

Glioblastoma Part II Molecular Targets and Clinical Trials An Issue of Neurosurgery Clinics of North America

Glioblastoma  Part II  Molecular Targets and Clinical Trials  An Issue of Neurosurgery Clinics of North America Book
Author : Linda M. Liau
Publisher : Elsevier Health Sciences
Release : 2021-04-08
ISBN : 0323813062
Language : En, Es, Fr & De

GET BOOK

Book Description :

This issue of Neurosurgery Clinics, guest edited by Dr. Linda M. Liau, is dedicated to Glioblastoma: Molecular and Clinical Trials. This issue is one of four selected each year by the series consulting editors, Drs. Russell R. Lonser and Daniel K. Resnick. Topics will include—but are not limited to—Pathology & Molecular Markers, Cellular States & Genetic Diversity in Glioblastoma, Mismatch Repair in Glioblastoma Resistance, Genetic Susceptibility in Brain Cancer, Pediatric Gliomas: Molecular Landscape & Emerging Targets, Molecularly Targeted Clinical Trials, Novel Radiation Sensitizers, Immunotherapy Checkpoint Inhibitors, Brain Tumor Vaccines, CAR T Cells, Oncolytic Virotherapy, Targeting Cancer Stem Cells, Therapeutic Delivery to CNS, Theranostics: Dual Modality PET Tracers, and Neuroimaging & Novel Response Assessments.

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy  Molecular Mechanisms and Innovative Reversal Strategies Book
Author : Ramasamy Paulmurugan,Tarik F. Massoud
Publisher : Academic Press
Release : 2021-06-25
ISBN : 0128215682
Language : En, Es, Fr & De

GET BOOK

Book Description :

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Systemic Drug Delivery Strategies

Systemic Drug Delivery Strategies Book
Author : Mansoor M. Amiji,Lara Scheherazade Milane
Publisher : Academic Press
Release : 2021-08-21
ISBN : 0323909256
Language : En, Es, Fr & De

GET BOOK

Book Description :

Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies. Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO

Therapeutic Brain Cancer Targeting by Gene Therapy and Immunomodulation

Therapeutic Brain Cancer Targeting by Gene Therapy and Immunomodulation Book
Author : Apostolos Stathopoulos
Publisher : Unknown
Release : 2012
ISBN : 9789461733634
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Therapeutic Brain Cancer Targeting by Gene Therapy and Immunomodulation book written by Apostolos Stathopoulos, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Impact of the Glioma Microenvironment on Antitumor Immunity

Impact of the Glioma Microenvironment on Antitumor Immunity Book
Author : Valérie Dutoit,Lukas Bunse,Payal Watchmaker
Publisher : Frontiers Media SA
Release : 2022-01-31
ISBN : 2889741915
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Impact of the Glioma Microenvironment on Antitumor Immunity book written by Valérie Dutoit,Lukas Bunse,Payal Watchmaker, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.